ValueScreener

ValueScreener company report

McKesson Corporation (MCK)

NYSE / Healthcare / Medical - Distribution

Share price

998.64 USD Market dataClose of Oct 15, 2026

Market capitalisation

116.40B USD Market dataClose of Oct 15, 2026
Market data
Oct 15, 2026
Filed accounts
FY2026, filed May 8, 2026
Ratios computed
Oct 15, 2026
Filed years
10, FY2017 to FY2026
Four kinds of sourceSEC filingCompany statementMarket dataComputedWhat each means
SEC filingFiled with the SEC
Read from a statement the company filed with the SEC, with the form, fiscal year, filing date and accession beside it.
Company statementCompany statement
What the company says about itself in a filing: an 8-K item, the auditor, its own segment names.
Market dataMarket data
Prices, market value and what analysts publish, with the date they are as of.
ComputedComputed by ValueScreener
Worked out by us from the other three, with the inputs and the formula one press away. A score is a research output, not a rating or a recommendation.
Reading

1 of 10

Overview

What the business is, what it costs, and how it reads on four questions.

Market dataSEC filingComputed

Four questions, at a glance

Quality

Return on invested capital, after tax

192.3% Computed

From the FY2026 filing

Read quality

Valuation

Price to earnings

25.91x Computed

FY2026 accounts, priced at the latest close

Read valuation

Cash generation

Free cash flow yield

4.6% Computed

FY2026 accounts, priced at the latest close

Read cash generation

Revenue and net income, as filed

FY2017 Revenue: 198.53B USDFY2017 Net income: 5.07B USDFY2018 Revenue: 208.36B USDFY2018 Net income: 67.0M USDFY2019 Revenue: 214.32B USDFY2019 Net income: 34.0M USDFY2020 Revenue: 231.05B USDFY2020 Net income: 900.0M USDFY2021 Revenue: 238.23B USDFY2021 Net income: -4.54B USDFY2022 Revenue: 263.97B USDFY2022 Net income: 1.11B USDFY2023 Revenue: 276.71B USDFY2023 Net income: 3.56B USDFY2024 Revenue: 308.95B USDFY2024 Net income: 3.00B USDFY2025 Revenue: 359.05B USDFY2025 Net income: 3.29B USDFY2026 Revenue: 403.43B USDFY2026 Net income: 4.76B USD
Revenue Net income10 filed fiscal years, from the annual reports; the table in Filings names each document.
Named tests met
3 of 30 Which tests
The business, and the score behind its five axes

The reading, in brief

Is it cheap

Price to earnings is 25.91x at the close of 2026-10-15 on FY2026 figures; the lines are 15.00x (Graham's defensive ceiling) and, by market convention, 10.00x, 25.00x and 40.00x, and this sits between 25.00x and 40.00x.

Today, against the Healthcare sector (223 companies), 25.91x sits at the 50th percentile; the middle half of that group runs from 13.52x to 42.98x.

Is it good

Return on invested capital was 192.3% in FY2026, in the band labelled "Exceptional" (20.0% and above), on lines anchored on Damodaran's cost-of-capital data, suggesting returns on the capital in the business well above the usual cost of that capital.

Today, against the Healthcare sector (233 companies), 192.3% sits at the 100th percentile; the middle half of that group runs from -37.4% to 12.8%.

Is it safe

Interest coverage was 25.15x in FY2026, in the band labelled "Comfortable" (6.00x and above), on lines anchored on Damodaran's interest-coverage table, suggesting an interest bill operating profit covers many times over.

Year by year against peers
Whether McKesson Corporation's gross margin stayed above the median of the Healthcare sector, year by year. (FY2017 to FY2026, 10 fiscal years of McKesson Corporation with a comparable figure)
The direction
Which way McKesson Corporation's gross margin has moved, and how steadily. (FY2017 to FY2026, 10 filed years of McKesson Corporation)
What could explain it
What in McKesson Corporation's filed statements could explain the movements. (8 readings drawn from the statement lines McKesson Corporation filed)
What to check next
What to check next on McKesson Corporation, and where in its filings. (4 questions for McKesson Corporation)
In one paragraph
One paragraph on McKesson Corporation's returns, cash, balance sheet and price. (14 of sixteen figures read for McKesson Corporation)

These are MCK’s filed figures. The research desk says what they mean, against peers and its own years, with what to check next.

Research MCKPart of Serious. New accounts start with 30 days of Professional, free, no card.

2 of 10

What changed

The newest filing, what it moved, and when the next one is due.

SEC filingCompany statement

The newest accounts on file are the FY2026 annual report: 10-K, filed May 8, 2026, accession 0000927653-26-000069.

3 of 10

Quality

The returns the business earns on its capital, and the margins behind them.

SEC filingComputed

McKesson Corporation: returns on capital and margins, each with its source
FigureValue, source and document
Return on invested capital, after tax192.3% ComputedFY2026 10-K, filed May 8, 2026, 0000927653-26-000069
Return on equity
Why n/m

Book equity is zero or negative. Return on equity computed over it flips sign and can read as a strong positive on a loss-making company, so we will not show a number.

n/m ComputedFY2026 10-K, filed May 8, 2026, 0000927653-26-000069
Return on capital employed, pre-tax40.6% ComputedFY2026 10-K, filed May 8, 2026, 0000927653-26-000069
Return on assets5.8% ComputedFY2026 10-K, filed May 8, 2026, 0000927653-26-000069
Gross margin3.6% ComputedFY2026 10-K, filed May 8, 2026, 0000927653-26-000069
Operating margin1.5% ComputedFY2026 10-K, filed May 8, 2026, 0000927653-26-000069
Net margin1.2% ComputedFY2026 10-K, filed May 8, 2026, 0000927653-26-000069
MCK 1.2%
CVS 0.4%CI 2.2%COR 0.5%CAH 0.7%TAK 2.4%
0.4%2.4%
Net margin: MCK against the 5 companies named under Valuation context, each as filed for its own latest year. Placement only: no average is drawn.

4 of 10

Financial strength

What it owes against what it owns, and whether it can meet what falls due.

SEC filingComputedCompany statement

McKesson Corporation: leverage, liquidity and distress, each with its source
FigureValue, source and document
Debt to equity
Why n/m

Filed shareholders equity is zero or below, so debt measured against it is not a measurement (n/m).

n/m ComputedFY2026 10-K, filed May 8, 2026, 0000927653-26-000069
Current ratio0.85 ComputedFY2026 10-K, filed May 8, 2026, 0000927653-26-000069
Quick ratio0.49 ComputedFY2026 10-K, filed May 8, 2026, 0000927653-26-000069
Interest coverage25.15x ComputedFY2026 10-K, filed May 8, 2026, 0000927653-26-000069
Altman Z-score6.27 ComputedClose of Oct 15, 2026 · FY2026 10-K, filed May 8, 2026, 0000927653-26-000069
Net debt4.83B ComputedFY2026 10-K, filed May 8, 2026, 0000927653-26-000069
Total assets 82.32BTotal liabilities 84.10BOwnsOwes, and equity
Total assets Total liabilities Shareholders’ equity (zero or below, not drawn)
The balance sheet, line by line

Financial health

What McKesson Corporation owned and owed at the end of fiscal 2026, from the balance sheet it filed (10-K, filed May 8, 2026, 0000927653-26-000069).

McKesson Corporation: balance sheet position
Total assets82.32B FiledFY2026 10-K, filed May 8, 2026
Total liabilities84.10B FiledFY2026 10-K, filed May 8, 2026
Shareholders' equity-2.17B FiledFY2026 10-K, filed May 8, 2026
Cash3.98B FiledFY2026 10-K, filed May 8, 2026
Total debt8.80B FiledFY2026 10-K, filed May 8, 2026
Net debt4.83B
Current ratio0.85
Debt to equityn/m
  • Debt to equity: FY2026: Filed shareholders equity is zero or below, so debt measured against it is not a measurement (n/m).

Read from the filed balance sheet for each year, with the income statement of the same year supplying operating profit where a ratio needs it. Nothing here is a view on whether this company is sound.

5 of 10

Valuation context

What the market charges for it, against its own record and companies like it.

Market dataSEC filingComputed

McKesson Corporation: what the market charges, each with its source
FigureValue, source and document
Price to earnings25.91x ComputedClose of Oct 15, 2026 · FY2026 10-K, filed May 8, 2026, 0000927653-26-000069
P/E on trailing twelve months26.79x ComputedClose of Oct 15, 2026 · Trailing four quarters, each as known on the day; the quarterly filings are listed under Filings
Price to book
Why n/m

Book equity is zero or negative, so a ratio measured against it (debt to equity, price to book) is not a measurement, and we will not show a number.

n/m ComputedClose of Oct 15, 2026 · FY2026 10-K, filed May 8, 2026, 0000927653-26-000069
Price to sales0.31x ComputedClose of Oct 15, 2026 · FY2026 10-K, filed May 8, 2026, 0000927653-26-000069
Enterprise value to EBIT20.73x ComputedClose of Oct 15, 2026 · FY2026 10-K, filed May 8, 2026, 0000927653-26-000069
Enterprise value to EBITDA19.81x ComputedClose of Oct 15, 2026 · FY2026 10-K, filed May 8, 2026, 0000927653-26-000069
Price to earnings over growth
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2026 10-K, filed May 8, 2026, 0000927653-26-000069
Diluted earnings per share38.38 USD FiledFY2026 10-K, filed May 8, 2026, 0000927653-26-000069
Graham number
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedFY2026 10-K, filed May 8, 2026, 0000927653-26-000069

We publish no fair value or price target of our own. Value MCK on your own assumptions in the DCF workbench, starting from the filed figures.

Its own record, and companies like it

Valuation

What the market charges for McKesson Corporation today, and the multiples it has carried. No value of ours: the figures are the filings’ and the market’s.

McKesson Corporation: valuation
Share price998.64 USD
Market capitalisation116.40B USD
Enterprise value to EBITDA19.81x
Graham numbern/a
Diluted earnings per share, FY202638.38 USD

Price to earnings on trailing twelve months, a different basis from the fiscal-year P/E above, since May 22, 2017: low 6.32x, median 26.10x, high 850.59x, latest 26.79x. 1,833 trading days with a meaningful ratio, 531 more on a loss and left out. Each close over the trailing twelve months of earnings as known that day: a quarter counts from the day it was filed.

Companies like McKesson Corporation

  1. CVS Health Corporation (CVS)Market cap 118.40B USD
  2. Cigna Corporation (CI)Market cap 78.96B USD
  3. Cencora, Inc. (COR)Market cap 65.15B USD
  4. Cardinal Health, Inc. (CAH)Market cap 58.75B USD
  5. Takeda Pharmaceutical Company Limited (TAK)Market cap 61.73B USD

Same sector (Healthcare) and size band (Large, 10B to 200B), nearest in market value, net margin and current ratio. Each of those counts equally, by how many of the companies considered sit between the two on it. Closest first: the order is likeness and nothing else.

6 of 10

Cash generation

Whether profit arrives as cash, and what is paid back to shareholders.

SEC filingComputed

McKesson Corporation: cash generation and what is paid out, each with its source
FigureValue, source and document
Free cash flow yield4.6% ComputedClose of Oct 15, 2026 · FY2026 10-K, filed May 8, 2026, 0000927653-26-000069
Free cash flow5.72B USD ComputedFY2026 10-K, filed May 8, 2026, 0000927653-26-000069
Free cash flow margin1.4% ComputedFY2026 10-K, filed May 8, 2026, 0000927653-26-000069
Dividend yield0.3% ComputedClose of Oct 15, 2026 · FY2026 10-K, filed May 8, 2026, 0000927653-26-000069
Payout ratio8.0% ComputedFY2026 10-K, filed May 8, 2026, 0000927653-26-000069
FY2017 Free cash flow: 4.34B USDFY2017 Net income: 5.07B USDFY2018 Free cash flow: 3.94B USDFY2018 Net income: 67.0M USDFY2019 Free cash flow: 3.61B USDFY2019 Net income: 34.0M USDFY2020 Free cash flow: 4.01B USDFY2020 Net income: 900.0M USDFY2021 Free cash flow: 4.09B USDFY2021 Net income: -4.54B USDFY2022 Free cash flow: 4.05B USDFY2022 Net income: 1.11B USDFY2023 Free cash flow: 4.77B USDFY2023 Net income: 3.56B USDFY2024 Free cash flow: 3.88B USDFY2024 Net income: 3.00B USDFY2025 Free cash flow: 5.55B USDFY2025 Net income: 3.29B USDFY2026 Free cash flow: 5.72B USDFY2026 Net income: 4.76B USD
Free cash flow Net incomeProfit that arrives as cash stands level with net income; a gap year after year is worth reading about.

7 of 10

Filings

Every figure, the year it is for and the document it was read from.

SEC filingMarket data

The filed figures

Computed from the accounts this company filed with the SEC and, in a ratio with a price in it, the last close, dated on this page. Every filed figure below carries the fiscal year and the filing date its accounts were read from, and every blank carries the reason it is blank. Nothing here is a view on this company.

McKesson Corporation: the eight ratios, with the fiscal year and filing date behind each.
FigureValueYearAs of
25.91xFY2026Oct 15, 2026
n/mFY2026Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
20.73xFY2026Oct 15, 2026
4.6%FY2026Oct 15, 2026
192.3%FY2026May 8, 2026
0.3%FY2026Oct 15, 2026
n/mFY2026May 8, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
0.85FY2026May 8, 2026
0.31xFY2026Oct 15, 2026
n/aFY2026Oct 15, 2026
n/a This figure compares a year against the one before it, and we hold one filed year for this company.
6.27FY2026Oct 15, 2026
-2.40FY2026May 8, 2026
6/9FY2026May 8, 2026

The figures are computed from the accounts for fiscal 2026, the newest full year on file. 10 filed fiscal years on record, FY2017 to FY2026, from SEC EDGAR. Prices as of Oct 15, 2026. Ratios recomputed Oct 15, 2026. Two facts, because a recompute is not a fresh quote.

The year and the filing date name the statement each figure’s accounts are read from, and they stand even where the figure itself could not be computed: the line beneath a blank says what that statement did not carry. A figure’s name opens its formula and the filings behind it; a statement that names no SEC filing has no filing date, and reads n/a.

Ten years of filed figures, year by year

Ten years of filed figures

10 filed fiscal years, FY2017 to FY2026, read from the annual reports McKesson Corporation filed with the SEC. Each year names its filing. Amounts in USD, as filed.

McKesson Corporation: revenue, earnings, free cash flow and returns, by fiscal year, with the filing each year was read from
YearRevenueOperating incomeNet incomeEPS, dilutedFree cash flowOperating marginReturn on equityFiling
FY2026403.43B6.21B4.76B38.385.72B1.5%n/m10-K, May 8, 20260000927653-26-000069
FY2025359.05B4.42B3.29B25.725.55B1.2%n/m10-K, May 9, 20250000927653-25-000036
FY2024308.95B3.91B3.00B22.393.88B1.3%n/m10-K, May 8, 20240000927653-24-000035
FY2023276.71B4.38B3.56B25.034.77B1.6%n/m10-K, May 9, 20230000927653-23-000038
FY2022263.97B2.04B1.11B7.234.05B0.8%n/m10-K, May 9, 20220000927653-22-000051
FY2021238.23B-5.04B-4.54B-28.264.09B-2.1%n/m10-K, May 12, 20210000927653-21-000039
FY2020231.05B2.49B900.0M4.954.01B1.1%17.7%10-K, May 22, 20200000927653-20-000033
FY2019214.32B886.0M34.0M0.173.61B0.4%0.4%10-K, May 15, 20190000927653-19-000009
FY2018208.36B762.0M67.0M0.323.94B0.4%0.7%10-K, May 24, 20180000927653-18-000010
FY2017198.53B7.12B5.07B22.734.34B3.6%45.7%10-K, May 22, 20170000927653-17-000007
  • Revenue, compound annual growth FY2017 to FY2026: 8.2%
  • Earnings, compound annual growth FY2017 to FY2026: -0.7%
  • Earnings per share, compound annual growth FY2017 to FY2026: 6.0%
  • Free cash flow, compound annual growth FY2017 to FY2026: 3.1%

Every figure in this section is a line of a filed annual statement or a ratio of two of them. Nothing here is estimated or smoothed. Earnings per share filed before a share split are put on today's share count, and say so. Nothing here is a verdict on the company.

8 of 10

Risks and guardrails

The accounting screens, the published tests, and the lines you can set to be told.

ComputedCompany statement

McKesson Corporation: accounting screens and published tests, each with its source
FigureValue, source and document
Beneish M-score-2.40 ComputedFY2026 10-K, filed May 8, 2026, 0000927653-26-000069
Piotroski F-score6/9 ComputedFY2026 10-K, filed May 8, 2026, 0000927653-26-000069
Named tests met3 of 30 Computed
Beta0.10 ComputedClose of Oct 15, 2026

The named tests

Of 30 tests value investors published: 3 met, 20 not met, 7 we could not complete. Counts, never a score: a single figure would have to decide that meeting one investor’s criteria and meeting another’s are worth the same.

Which tests, by name(all 30)
Meets
ROIC at or above WACC; Low P/S, rising earnings (James O'Shaughnessy); Cash-covered dividend
Does not
Defensive investor (Benjamin Graham); Large cap, low P/E; Earnings yield and ROIC (Joel Greenblatt); High F-score, low P/B (Joseph Piotroski); Three forensic scores; Gross margin, turnover (Robert Novy-Marx); EV/EBITDA and coverage; High yield, low payout; Dividends and buybacks; Near the 52-week low; Z-score and coverage (Edward Altman); Two thirds of NCAV (Benjamin Graham); High returns, low debt; Owner earnings yield; High return on tangibles; Tangible book or below; Cash-flow yield and ROIC; Clean books, high ROIC; Cheapest quarter on P/E (David Dreman); Low P/E, growth, yield (John Neff)
Not measured
Deep value; Low PEG, low debt (Peter Lynch); High returns and growth; Low beta, profitable; P/E times P/B (Benjamin Graham); Book or below, low debt (Walter Schloss); Cheapest quarter on P/B (David Dreman). A test with a figure we could not read is incomplete, never met and never failed.
Figures we could not read(7)
  • Debt to Equity: Filed shareholders equity is zero or below, so debt measured against it is not a measurement (n/m).
  • P/B Ratio: Book equity is zero or negative, so a ratio measured against it (debt to equity, price to book) is not a measurement, and we will not show a number.
  • PEG Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Eps Growth 5Y: We do not hold this figure for this company, so there is nothing to show.
  • Return on Equity: Book equity is zero or negative. Return on equity computed over it flips sign and can read as a strong positive on a loss-making company, so we will not show a number.
  • Price To Graham: We do not hold this figure for this company, so there is nothing to show.
  • Price Tangible Book: Book equity is zero or negative, so a ratio measured against it (debt to equity, price to book) is not a measurement, and we will not show a number.

9 of 10

Declared positions

Whether anybody here owns this company.

Positions declared by Javier Sanz Alvarez: no holding in any company shown here, as of October 3, 2026.

10 of 10

Next step

What to do with what you have read.

A thesis is your reason for owning it, in your words, with the figures that must stay true. Checking those figures every night against the newest filed accounts, and telling you once when one breaks, is what the subscription adds.

More on this company

What this cannot tell you

  • 7 figures could not be read on this company, among them Debt to Equity, P/B Ratio, PEG Ratio. Each blank in the table above names the rest, with its reason. 7 named tests come back incomplete because of them, which is neither met nor missed.

And the one that is true of all of it: This is what the numbers say today. It cannot tell you the day one of them stops being true. Nothing here can, because the reasons are not written down.

Running this once is arithmetic on public documents and you are welcome to it. Writing down why you own each company, in your own words and with the numbers that have to stay true for it to hold, and then having those numbers re-checked every night against the newest filed accounts, and against the latest close where a rule watches a price, is Professional, the plan a new account starts on for 30 days, one trial per person. It writes to you the day one breaks, and stays quiet when nothing does. The check runs every night at 23:30 UTC. A filing is picked up the night after it is published.

No card. 30 free days, and nothing is charged unless you choose a plan.

Analyze your own portfolio

ValueScreener · valuescreener.ai · Computed from accounts filed with the SEC by this company, read from EDGAR, and from dated closing prices. On this page a filed figure opens into its formula, its inputs and the statement, fiscal year and filing date it was read from, and a price into the day of its close. A figure that cannot show that trail says so.

A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.

Once a week, what changed in the filings of US-listed companies, why it can matter to a thesis, and what deserves a closer review. Grounded in filings, not market noise.

Site map
  • Android app coming soon
  • iPhone app coming soon
ValueScreener

Discover companies, research each one to its filings, track what matters, and take your work into your own spreadsheet.

ValueScreener is a trading name of Oliva Real Estate Technologies LLC, a Delaware limited liability company. Legal notices: legal@valuescreener.ai. © 2026 Oliva Real Estate Technologies LLC. All rights reserved.

Risk disclaimer. This service is provided for research and education only. Nothing on it is investment advice, a recommendation, or an offer to buy or sell any security. Capital is at risk, and past performance does not indicate future results. Figures come from filed accounts and may be incomplete, delayed or later restated, so verify a number against the filing before you act on it.